Crisaborole topical ointment, 2%: A nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis

Journal of Drugs in Dermatology

Volumn 15, Issue 4, 2016, Pages 390-395

  Jarnagin, Kurt ^a   Chanda, Sanjay ^b   Coronado, Dina ^a   Ciaravino, Vic ^a   Zane, Lee T ^a   Guttman Yassky, Emma ^b   Lebwohl, Mark G ^b  

^a PFIZER INC   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISABOROLE; CYCLIC AMP; PHOSPHODIESTERASE IV; BORON DERIVATIVE; CYTOKINE; FUSED HETEROCYCLIC RINGS; NONSTEROID ANTIINFLAMMATORY AGENT; OINTMENT; PHOSPHODIESTERASE IV INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG IDENTIFICATION; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; NONHUMAN; OINTMENT; PHYSICAL CHEMISTRY; PRECLINICAL STUDY; PRURITUS; SYSTEMIC CIRCULATION; TOPICAL DRUG ADMINISTRATION; TOPICAL TREATMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DERMATITIS, ATOPIC; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BORON COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CYTOKINES; DERMATITIS, ATOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; OINTMENTS; PHOSPHODIESTERASE 4 INHIBITORS; TREATMENT OUTCOME;

EID: 84978940583     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22:192-199.
2. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483-1494.
3. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73:311-318.
4. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135:324-336.
5. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. 2014;2:371-379.
6. Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1:142-151.
7. National Collaborating Centre for Women’s and Children’s Health. Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years. London, United Kingdom: RCOG Press. 2007.
8. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-132.
9. Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009;19:2129-2132.
10. Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20:22608.
11. Tan Y, Watkins AA, Freeman BB, et al. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015;194:101-112.
12. Noh AL, Yang M, Lee JM, et al. Phosphodiesterase 3 and 4 negatively regulate receptor activator of nuclear factor-kappaB ligand-mediated osteoclast formation by prostaglandin E2. Biol Pharm Bull. 2009;32:1844-1848.
13. Jimenez JL, Iniguez MA, Munoz-Fernandez MA, Fresno M. Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal. 2004;16:1363-1373.
14. Freund YR, Akama T, Alley MR, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012;586:3410-3414.
15. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10:1236-1242.
16. Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62:151-161.
17. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769-779.
18. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344-1354.
19. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8:364-372.
20. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17-26.
21. Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate- phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol. 1993;100:681-684.
22. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol. 1995;105:84S-88S.
23. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107:51-56.
24. Volf EM, Au SC, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11:341-346.
25. Higgs G. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs. 2010;11:495-498.
26. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
27. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-1026.
28. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857-866.
29. Del Rosso JQ, Plattner JJ. From the test tube to the teatment room: fundamentals of boron-containing compounds and their relevance to dermatology. J Clin Aesthet Dermatol. 2014;7:13-21.
30. Rainey CJ, Nyquist LA, Christensen RE, et al. Daily boron intake from the American diet. J Am Diet Assoc. 1999;99:335-340.
31. Ciaravino V, Plattner J, Chanda S. An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013;54:338-346.
32. Kircik L, Call R, Tschen E, et al. Maximal use systemic exposure (MUSE) study evaluating AN2728 topical ointment, 2%, a boron-based small molecule for the treatment of mild-to-moderate atopic dermatitis in children 2 to 17 years of age [poster]. Presented at the Annual Meeting of the European Society for Dermatological Research, September 10-13, 2014, Copenhagen, Denmark.
33. Stein Gold LF, Spelman L, Spellman MC, et al. A phase 2, randomized, controlled, dose-ranging study evaluating AN2728 topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14:1394-1399.
34. Murrell DF, Gebauer K, Spelman L, Zane LT. AN2728 topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14:1108-1112.
35. Zane LT, Tom WL, Chanda S, Liu L, Van Syoc M. Safety, pharmacokinetics and efficacy of AN2728 ointment, 2% in a phase 2 study of adolescents with mild-to-moderate atopic dermatitis [poster]. Presented at the International Investigative Dermatology Meeting, May 8-11, 2013, Edinburgh, Scotland.